Cellzome set to raise City profile

German drug discovery and proteomics firm Cellzome has drafted in Hogarth Partnership to raise its profile among City investors only three months after opening UK offices in Cambridge.

Hogarth has been charged with a six-month project contract. The account will be led by agency partner John Olsen and agency head of life sciences Melanie Toyne-Sewell.

The appointment marks a ramping up of the privately owned firm’s fundraising strategy among City fund managers and investors.

‘At this stage, our work will be aimed primarily at positioning Cellzome among fund managers and City investors,’ said Toyne-Sewell.

Cellzome, based in Heidelberg Germany, focuses on discovering new medicines for chronic human diseases, in particular Alzheimer’s Disease.

An international team of 100 staff across operations in Cambridge and Heidelberg is building a pipeline of drug candidates. The company is also seeking drug-discovery partnerships with major pharma firms. Such partnerships already in place include research collaborations with Johnson & Johnson Pharmaceuticals R & D and Bayer HealthCare.

* Cambridge-based biotech company Bio Wisdom has appointed Hogarth Partnership for a positioning campaign aimed at City investors.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.